WP16302 A BIOEQUIVALENCE STUDY COMPARING GANCICLOVIR FROM THE VALGANCICLOVIR SYRUP FORMULATION AND THE COMMERCIAL VALGANCICLOVIR 450MG TABLET (VALCYTE®) AT A DOSE OF 900MG IN KIDNEY TRANSPLANT RECIPIENTS: